Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (7): 40-43.doi: 10.6040/j.issn.1671-7554.0.2019.362

Previous Articles    

Advances in the diagnosis and treatment of multiple myeloma

LU Jin   

  1. Peking University Peoples Hospital, Institute of Hematology of Peking University;
    Collaborative Innovation Center of Hematology, Beijing 100044, China
  • Published:2022-09-27

PDF (PC)

9

Abstract: The diagnosis, treatment and efficacy evaluation of multiple myeloma are progressing rapidly in recent years. Novel agents including new proteasome inhibitors, new immunomodulators, monoclonal antibodies and cellular therapy have non-stoppingly updated the diagnostic criteria, diagnostic methods and evaluation criteria. This article reviews the current progress in diagnosis and treatment of multiple myeloma in order to guide clinical practice.

Key words: Multiple myeloma, Diagnostic criteria, Evaluation criteria, Treatment

CLC Number: 

  • R733.3
[1] Krönke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells [J]. Science, 2014,343(6168): 301-305.
[2] Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins [J]. Science, 2014,343(6168): 305-309.
[3] Hansford BG, Silbermann R. Advanced imaging of multiple myeloma bone disease [J]. Front Endocrinol(Lausanne), 2018, 9: 436. doi: 10.3389/fendo.2018.00436.
[4] Terpos E, Ntanasis-Stathopoulos I, Dimopoulos MA. Myeloma bone disease: from biology findings to treatment approaches [J]. Blood, 2019, 133(14): 1534-1539.
[5] Milani P, Murray DL, Barnidge DR, et al. The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic [J]. Am J Hematol, 2017, 92(8): 772-779.
[6] Moore LM, Cho S, Thoren KL: MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins [J]. Clin Chim Acta, 2019, 492: 91-94. doi: 10.1016/j.cca.
[7] 宋萍, 安志明, 周小钢, 等. 血清游离轻链的检测及其在轻链型多发性骨髓瘤中的临床意义[J]. 中国实验血液学杂志, 2015, 23(5): 1357-1361. SONG Ping, AN Zhiming, ZHOU Xiaogang, et al. Test of serum free light chain and its clinical significance in light chain multiple myeloma [J]. Journal of Experimental Hematology, 2015, 23(5): 1357-1361.
[8] Dejoie T, Corre J, Caillon H, et al. Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma [J]. Blood, 2016, 128(25): 2941-2948.
[9] 王亚哲, 路瑾, 郝乐, 等. 4色与8色荧光抗体组合检测多发性骨髓瘤患者微小残留病的比较分析[J]. 中华血液学杂志, 2017, 38(4): 272-278. WANG Yazhe, LU Jin, HAO Le,et al.Comparison and analysis of minimal residual disease in multiple myeloma patients detected by 4-color and 8-color fluorescence antibody panels [J].Chinese Journal of Hematology, 2017, 38(4): 272-278.
[10] Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis [J]. JAMA Oncol, 2017, 3(1): 28-35.
[11] Lahuerta JJ, Paiva B, Vidriales MB, et al. Depth of response in multiple myeloma: a pooled analysis of three pethema/gem clinical trials [J]. J Clin Oncol, 2017, 35(25): 2900-2910.
[12] Durie BG, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant(SWOG S0777): a randomised, open-label, phase 3 trial [J]. Lancet, 2017, 389(10068): 519-527.
[13] Jacobus SJ, Rajkumar SV, Weiss M, et al. Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone(VRd)vs bortezomib-dexamethasone(Vd)for patients with multiple myeloma who have completed a dexamethasone based induction regimen [J]. Blood Cancer J, 2016, 6(7): 448.
[14] Moreau P, Hulin C, Macro M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial [J]. Blood, 2016, 127(21): 2569-2574.
[15] Goldschmidt H, Lokhorst HM, Mai EK, et al. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial [J]. Leukemia, 2018, 32(2): 383-390.
[16] Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma [J]. N Engl J Med, 2017, 376(14): 1311-1320.
[17] Facon T, Dimopoulos MA, Dispenzieri A, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma [J]. Blood, 2018, 131(3): 301-310.
[18] 王国苗, 杨光忠, 黄仲夏, 等, 中国多发性骨髓瘤患者接受来那度胺的多中心非干预性前瞻性观察研究[J]. 中华内科杂志, 2017, 56(7): 500-506. WANG Guomiao, YANG Guangzhong, HUANG Zhongxia, et al. A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma [J]. Chinese Journal of Internal Medicine, 2017, 56(7): 500-506.
[19] Lu J, Lee JH, Huang SY, et al. Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial [J]. Br J Haematol, 2017, 176(5): 743-749.
[20] Facon T. Phase 3 randomized study of daratumumab plus lenalidomide and dexamethasone(D-Rd)versus lenalidomide and dexamethasone(Rd)in patients with newly diagnosed multiple myeloma(NDMM)ineligible for transplant(MAIA)[J]. ASH abstract LBA-2, 2018.
[21] Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma [J]. N Engl J Med, 2018, 378(6): 518-528.
[22] ODonnell EK, Laubach JP, Yee AJ, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma [J]. Br J Haematol, 2018, 182(2): 222-230.
[23] Jones JR, Weinhold N, Ashby C, et al. Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients[J]. Haematologica, 2019, 7. doi: 10.3324/haematol.
[24] Johnsen HE, Bogsted M, Schmitz A, et al.The myeloma stem cell concept, revisited: from phenomenology to operational terms [J]. Haematologica, 2016, 101(12): 1451-1459.
[25] Lin L, Cao L, Liu Y, et al.B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src/STAT3 and c-Cbl-mediated degradation of SOCS3 [J]. Leukemia, 2018, 20. doi: 10.1038/s41375-018-0331-6.
[26] Lin L, Zhang X, Cao L, et al. Reelin promotes adhesion of multiple myeloma cells to bone marrow stromal cells via integrin beta1 signaling [J]. J Cancer, 2017, 8(12): 2212-2222.
[27] Lakshman A, Painuly U, Rajkumar SV, et al. Natural history of multiple myeloma with de novo del(17p)[J]. Blood Cancer J, 2019, 9(3): 32.
[28] Ziogas DC, Dimopoulos MA, Kastritis E. Prognostic factors for multiple myeloma in the era of novel therapies [J]. Expert Rev Hematol, 2018, 11(11): 863-879.
[29] Lagana A, Beno I, Melnekoff D, et al. Precision medicine for relapsed multiple myeloma on the basis of an integrative multiomics approach [J]. JCO Precis Oncol, 2018. doi: 10.1200/PO.18.00019.
[30] Lohr JG, Stojanov P, Carter SL, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy [J]. Cancer Cell, 2014, 25(1): 91-101.
[31] Harding T, Baughn L, Kumar S, et al. The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies [J]. Leukemia, 2019, 33(4): 863-883.
[32] Matulis SM, Gupta VA, Neri P, et al. Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma [J]. Leukemia, 2019, 33(5): 1291-1296.
[33] Heuck CJ, Jethava Y, Khan R, et al. Inhibiting MEK in MAPK pathway-activated myeloma [J]. Leukemia, 2016, 30(4): 976-980.
[1] JIANG Ziqing, ZENG Yanping, JI Xiaodong, ZUO Junling. A case report of hemophagocytic syndrome secondary to talaromyces marneffei infection [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 91-97.
[2] Chao PENG,Yingfang ZHOU. Progress on the medical treatment of adenomyosis [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 20-25.
[3] KONG Xinxin, SUN Shuzhen, LI Qian, CHEN Yuan, ZHOU Aihua, WANG Li, YAO Xiujun. Analysis of 7 cases of anti-H factor antibody-positive hemolytic uremic syndrome [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 82-86.
[4] SONG Yufeng, NING Hao, YAO Zhigang, WU Haihu, LIU Feifan, LYU Jiaju. Clinical and imaging features of adrenal cavernous hemangioma [J]. Journal of Shandong University (Health Sciences), 2022, 60(2): 37-42.
[5] PAN Pengfei, XU Lisheng, JI Kunqian, WANG Dexiang, LI Yu. Mitochondrial myopathy beginning with respiratory failure: one case and literature review [J]. Journal of Shandong University (Health Sciences), 2022, 60(2): 54-59.
[6] Yifeng WANG,Liqing HE. Research progress on surgery of inguinal lymph nodes in vulvar cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 103-109,116.
[7] Chunfang HA,Ruyue LI. Research progress of drug resistance in ovarian cancer and targeted therapy strategy [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 117-123.
[8] Kefang WANG,Chen WU. Dilemmas and thoughts on solutions of adherence to chronic disease management [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 124-129.
[9] WANG Zhe, LIU Yujie, MAO Qian, GUAN Peixia, BAO Qihan, LI Chengsheng, QIAO Xiaowei, PAN Qingzhong, WANG Suzhen. Evaluation of the efficacy of different regimens for early triple negative breast cancer based on the inverse probability of treatment weighting method [J]. Journal of Shandong University (Health Sciences), 2021, 59(8): 113-118.
[10] Haipeng SI,Wencan ZHANG,Le LI,Xin ZHOU. Research advances on risk factors, diagnosis and treatment of Kümmell's disease [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 25-32.
[11] ZENG Rong, WU Jinxiang, ZHANG Jintao, SHANGGUAN Hong, ZHOU Shengyu, TIAN Tian, DONG Liang. Primary pulmonary angiosarcoma: a case report and literature review [J]. Journal of Shandong University (Health Sciences), 2021, 59(2): 19-25.
[12] PENG Xiumiao, WANG Xuefeng, GONG Weimei, ZHANG Yang, ZHOU Jingwen, CUI Liangliang. Concentration changes and health risk of 8 heavy metals in drinking water in Jinan from 2016 to 2020 [J]. Journal of Shandong University (Health Sciences), 2021, 59(12): 24-32.
[13] Guoyun WANG,Kai WANG,Ming YUAN,Zijiang CHEN. Multidimensional management system for endometriosis (The Program for Shandong Province) [J]. Journal of Shandong University (Health Sciences), 2021, 59(10): 1-16.
[14] HUO Suxia, LIU Wei, WANG Xin. Experience in the treatment of 86 cases of type Ⅲ cesarean scar pregnancy [J]. Journal of Shandong University (Health Sciences), 2021, 59(1): 40-44.
[15] CHAI Jiawei, ZHU Kunbing, LI Yaqiong, WANG Tiantian. Occult thyroid carcinoma: a report of a rare case and review of literature [J]. Journal of Shandong University (Health Sciences), 2021, 59(1): 83-87.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd